XYXudong Yan

Xudong Yan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xudong Yan has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Ying Liu

    Department of Pediatrics, Peking University Shenzhen Hospital, China

    3 shared publications
  • Zhangbin Yu

    Department of Neonatology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China

    3 shared publications
  • Cheng Chen

    Department of Neonatology, Longgang District Maternity & Child Healthcare Hospital of Shenzhen City (Longgang Maternity and Child Institute of Shantou University Medical College), China

    2 shared publications
  • Dan Dan Rao

    Neonatology, Shenzhen Luohu Hospital Group Luohu People's Hospital, Shenzhen, Guangdong, China

    2 shared publications
  • Jiebo Liu

    Neonatology, Shenzhen Luohu Hospital Group Luohu People's Hospital, Shenzhen, Guangdong, China

    2 shared publications
  • Ping Zhou

    Department of Neonatology, Baoan Women’s and Children’s Hospital, Shenzhen, China

    2 shared publications

Latest Publications

  • Open Access

    A nomogram for predicting the risk of bronchopulmonary dysplasia in preterm infants: a prospective multicenter study

    by Yanping Guo, Hua Peng, Songzhou Xu, Zhangbin Yu, Xudong Yan, Ying Liu, Guobing Chen

    Background: Bronchopulmonary dysplasia (BPD) is a common and serious complication in very preterm infants, with potential long-term adverse effects. This study aimed to analyze the perinatal and postnatal risk factors for BPD in preterm infants, and to develop and validate a risk model for early postnatal risk stratification based on information available within the first 7 days of life. Methods: Data on preterm infants with gestational age < 32 weeks were prospectively collected from 28 hospitals in Shenzhen from January 2022 to December 2023. Neonates admitted to the NICU of Peking University Shenzhen Hospital and Shenzhen People’s Hospital were designated as the external validation cohort, whereas those from the other 26 NICUs were randomly divided into training and internal validation cohorts in an 8:2 ratio. BPD was the primary outcome and was diagnosed based on the 2018 revised criteria. Predictive factors were identified from the training cohort using logistic regression, and a nomogram model was constructed. Model performance was evaluated in terms of discrimination, calibration, and potential clinical utility. Results: A total of 1,336 preterm infants were included, with 801 in the training cohort, 214 in the internal validation cohort, and 321 in the external validation cohort. Among them, 259 infants (19.39%) were diagnosed with BPD. The nomogram model was based on six predictive factors: gestational age, birth weight (per 100 g increase), occurrence of preterm premature rupture of membranes (PPROM), antenatal corticosteroid (ACS) administration, early onset sepsis, and invasive mechanical ventilation (IMV) within the first seven days of life. The area under the curve (AUC)s were 0.812, 0.783, and 0.810 in the training, internal validation, and external validation cohorts, respectively, indicating acceptable discrimination. Calibration showed reasonable agreement between predicted and observed outcomes. Decision curve analysis suggested potential net benefit across a range of threshold probabilities, although clinical interpretation remains exploratory. Conclusion: This nomogram provides early postnatal risk stratification of BPD based on routinely available clinical information within the first week of life and may help identify preterm infants at higher risk.

  • Open Access

    Identification of serum metabolite biomarkers in premature infants with bronchopulmonary dysplasia: protocol for a multicentre prospective observational cohort study

    by Yanping Guo, Wanxiang He, Songzhou Xu, XuDong Yan, Shengnan He, Ping Zhou, Cheng Chen, Xin Guo, Jun Chen, Ruolin Zhang, et al.

    Introduction Bronchopulmonary dysplasia (BPD) is one of the most common and significant complications of preterm birth. It ultimately leads to a decrease in the quality of life for preterm infants and impacts their long-term health. Early prediction and timely intervention are crucial to halting the development of BPD. This study aims to identify the biomarkers that can predict the early occurrence and development of BPD by screening serum metabolites in preterm infants. This will provide strong support for the early prediction of BPD and targeted interventions in future research. Methods and analysis This is a prospective, multicentre, open-label, observational cohort study spanning 3 years. It will be conducted in six major neonatal intensive care units in Shenzhen, China, involving preterm infants born at gestational ages Ethics and dissemination Our protocol has been approved by the Medical Ethics Committees of all participating hospitals, including Peking University Shenzhen Hospital, Shenzhen People’s Hospital, Shenzhen Baoan Women’s and Children’s Hospital, Longgang District Maternity and Child Healthcare Hospital, Nanshan Maternity and Child Healthcare Hospital and Shenzhen Luohu People’s Hospital. We will disseminate our study results through academic conferences and peer-reviewed public journals. Trial registration number ChiCTR2400081615.


  • Open Access

    Multicentre online registration of bronchopulmonary dysplasia in very preterm infants in China: protocol for a prospective, open, observational cohort study

    by Shengnan He, Haibo Peng, Ping Zhou, Fei Hu, Xudong Yan, Qian Su, Boshi Yu, Yubai Li, Cheng Chen, Xin Guo, et al.

    Introduction Bronchopulmonary dysplasia (BPD) in very preterm infants (VPIs) has adverse long-term outcomes and affects the quality of survival. There are no registry studies on BPD in VPIs in China. Our aim was to conduct a prospective, multicentre, open, longitudinal, observational cohort study to investigate the epidemiological characteristics, diagnosis, treatment, and short-term and long-term outcomes of BPD in a real-life setting in China and lay the grounds for establishing a nationwide registry with clinical data and biological specimens. Methods This study aims to recruit a minimum of 2000 VPIs and start research in January 2024 in Shenzhen, China. We will collect clinical data from the beginning of the life of VPIs and follow them up to 3 years old. Short-term outcomes, such as the incidence of BPD, necrotising enterocolitis, retinopathy of prematurity, intraventricular haemorrhage and porencephalic ventricular leukomalacia, as well as the cost of hospitalisation, are the major variables of concern. Bayley-III Scale assessment, gross motor function and pulmonary function evaluation will be performed at the age of correction, that is, 18–24 months and 30–36 months. The follow-up outcomes include loss to follow-up, survival status, moderate-to-severe neurodevelopmental deficits and severe respiratory complications. Cord blood, peripheral blood, tracheal aspirate, faeces and urine from VPIs, as well as mother’s milk, will be collected and stored at −80°C. All the data will be registered, stored and managed in a cloud-based database. This knowledge will be useful for establishing diagnostic criteria and predictive models for BPD in the Chinese population. Ethics and dissemination Our protocol has been approved by the Medical Ethics Committee of Shenzhen People’s Hospital (LL-KY-2023174-02) and the local ethics committee of each participating centre. Our goal is to present our findings at national conferences and in peer-reviewed paediatric journals. Trial registration number Chinese Clinical Trial Registry (ChiCTR2400081615).


  • Open Access

    Factors influencing the development and implementation of pediatrics in family-centered care model: A scoping review

    by Peng Yue Ming, Shan Yuan, Yan Xudong

    Introduction: Family-Centered Care (FCC) in neonatal healthcare emphasizes collaborative efforts between medical staff and families. This approach, rooted in mutual respect and active family participation, aims to enhance infant care outcomes. However, understanding the underlying forces behind FCC interventions remains challenging due to the diverse methods employed in healthcare practices. Methods: We conducted a scoping review in June 2023. We searched Embase, Medline, CINAHL, Web of Science, Cochrane Library, Joanna Briggs Institute (JBI), PubMed, and PsycINFO. Inclusion criteria encompassed English language studies on Family-centered care and related factors, without date or geographic restrictions. Results: Fifteen pertinent studies meeting the inclusion criteria were identified. Five pivotal components of modern FCC emerged: effective communication, active patient and family involvement, robust family support systems, organizational considerations, and the nurturing attitude of nurses. Discussion: Family-centered care emerges as a comprehensive healthcare approach focusing on the interdependence of patients, healthcare professionals, and families. By recognizing this interconnection, FCC seeks to ensure the satisfaction and well-being of all stakeholders. Implementing FCC strategies presents challenges, emphasizing the need for continuous exploration and refinement. Conclusion: Embracing family-centered care principles enriches patient-centered healthcare by involving families as active partners in the care process. Acknowledging the integral role of families enhances care quality and contributes to improved patient outcomes. Ongoing research and dialogue are essential for refining FCC models, ensuring successful implementation, and fostering patient-centered healthcare environments.